Disparities in Adjuvant Radioactive Iodine Use in High-Risk Follicular Thyroid Carcinoma: Evaluation of NCCN and ATA Guideline Concordance.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
thyroidectomy between 2004 and 2022
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] RAI is associated with improved survival in high-risk FTC, yet disparities by race and insurance status persist. These findings highlight the need to improve equitable access to guideline-concordant treatment in high-risk populations.
OpenAlex 토픽 ·
Thyroid Cancer Diagnosis and Treatment
Thyroid Disorders and Treatments
Thyroid and Parathyroid Surgery
[INTRODUCTION] Radioactive iodine (RAI) therapy is recommended for high-risk follicular thyroid carcinoma (FTC).
APA
Alexandra H. Helbing, Tony Boualoy, et al. (2026). Disparities in Adjuvant Radioactive Iodine Use in High-Risk Follicular Thyroid Carcinoma: Evaluation of NCCN and ATA Guideline Concordance.. The Journal of surgical research. https://doi.org/10.1016/j.jss.2026.03.110
MLA
Alexandra H. Helbing, et al.. "Disparities in Adjuvant Radioactive Iodine Use in High-Risk Follicular Thyroid Carcinoma: Evaluation of NCCN and ATA Guideline Concordance.." The Journal of surgical research, 2026.
PMID
42031638 ↗
Abstract 한글 요약
[INTRODUCTION] Radioactive iodine (RAI) therapy is recommended for high-risk follicular thyroid carcinoma (FTC). However, factors influencing its use remain poorly defined. This study evaluated predictors of RAI use and outcomes among high-risk FTC patients using 2015 American Thyroid Association (ATA) and National Comprehensive Cancer Network (NCCN) classifications.
[MATERIALS AND METHODS] The National Cancer Database was queried for adults with FTC who underwent thyroidectomy between 2004 and 2022. Patients were classified as high risk based on 2015 ATA and NCCN criteria. Multivariable logistic and Cox regression models assessed predictors of RAI use and overall survival.
[RESULTS] Among 7943 FTC patients, 6411 (80.7%) were classified as high risk by NCCN and 7466 (94.0%) by ATA criteria. RAI was administered to 67.7% (NCCN) and 67.8% (ATA) of high-risk patients. Hispanic (ATA odds ratio [OR], 0.77; NCCN OR, 0.76) and Asian (ATA OR, 0.72; NCCN OR, 0.76) patients had lower odds of RAI receipt. Positive margins, T3-T4 tumors, and total thyroidectomy were associated with greater RAI use. RAI was linked to reduced mortality in both NCCN (hazard ratio 0.74) and ATA (hazard ratio 0.74) cohorts. Black race, Medicaid insurance, and poorly differentiated tumors were independently associated with increased mortality, along with T4 stage and distant metastases.
[CONCLUSIONS] RAI is associated with improved survival in high-risk FTC, yet disparities by race and insurance status persist. These findings highlight the need to improve equitable access to guideline-concordant treatment in high-risk populations.
[MATERIALS AND METHODS] The National Cancer Database was queried for adults with FTC who underwent thyroidectomy between 2004 and 2022. Patients were classified as high risk based on 2015 ATA and NCCN criteria. Multivariable logistic and Cox regression models assessed predictors of RAI use and overall survival.
[RESULTS] Among 7943 FTC patients, 6411 (80.7%) were classified as high risk by NCCN and 7466 (94.0%) by ATA criteria. RAI was administered to 67.7% (NCCN) and 67.8% (ATA) of high-risk patients. Hispanic (ATA odds ratio [OR], 0.77; NCCN OR, 0.76) and Asian (ATA OR, 0.72; NCCN OR, 0.76) patients had lower odds of RAI receipt. Positive margins, T3-T4 tumors, and total thyroidectomy were associated with greater RAI use. RAI was linked to reduced mortality in both NCCN (hazard ratio 0.74) and ATA (hazard ratio 0.74) cohorts. Black race, Medicaid insurance, and poorly differentiated tumors were independently associated with increased mortality, along with T4 stage and distant metastases.
[CONCLUSIONS] RAI is associated with improved survival in high-risk FTC, yet disparities by race and insurance status persist. These findings highlight the need to improve equitable access to guideline-concordant treatment in high-risk populations.